Global Primary Biliary Cirrhosis Drug Market By Product Type (Budesonide, FFP-104) And By End-Users/Application (Clinic, Hospital) Global Market Share, Forecast Data, In-Depth Analysis, And Detailed Overview, and Forecast, 2013 - 2026

  • AMR-984667
  • April 2021
  • Pharmaceuticals
  • 117 Pages

Report Preview

The Primary Biliary Cirrhosis Drug market research report provides an in-depth analysis of the currents trends, latest developments, scenario, market size, various drivers, restraints, and major players along with their profile details. Research report offers the historic data for year 2018 and 2019 and also provides the forecast data from year 2020 to 2028 which is based on revenue (USD Million). With the help of all these information research report helps the market participants to improve market positions. With the help of all these insights Primary Biliary Cirrhosis Drug market research report recommends a business strategy for present market participants to strengthen their position in the market.

According to the report, the Primary Biliary Cirrhosis Drug market size was USD xx million and it is expected to reach USD xx million by the end of 2028, with a CAGR of xx% during 2020-2028. While considering the volume shipments the global Primary Biliary Cirrhosis Drug market stood at xx (Units/Tons) in 2020 and expected to cross near about xx (units/Tons) by the end of forecast period.

Furthermore, the research report includes the detailed information about major players and provides the data regarding the current market scenario as well as upcoming market opportunities or challenges. Similarly, in segment report covers the types, and applications according to the countries and key regions. The research report consists the various drivers and restraints for Primary Biliary Cirrhosis Drug market along with their effects over the forecast period. Similarly, according to the region Primary Biliary Cirrhosis Drug market research report includes the study of opportunities available in the market situation.

The Primary Biliary Cirrhosis Drug market research report provides the in-depth data analysis by using the various graphs, figures, charts, and tables. Furthermore, the report provides the different business challenges which are impacting market growth in all direction.
 
Report Parameters Details of Parameter
Market Size xx Million
Based Year 2019
Forecast Period Covered 2019 – 2028
Units for value Revenue in USD million and CAGR from 2020 to 2028
Covered Segments Component, Types, Applications, End-Users, and more.
Product Type Budesonide, FFP-104, GSK-2330672, MBX-8025, NGM-282, Others
Applications Clinic, Hospital, Others
Region Covered North America, Europe, Asia Pacific, Latin America, Middle East and Africa
Companies Covered AlbireoPharma, CymaBay Therapeutics, Inc., Dr. Falk Pharma GmbH, Enanta Pharmaceuticals, Inc., GlaxoSmithKline Plc, Intercept Pharmaceuticals, Inc., Johnson & Johnson, MediGene AG, NGM Biopharmaceuticals, Inc., Virobay Inc.

Global Primary Biliary Cirrhosis Drug Market Segmentation by Regions:
In regional analysis, Primary Biliary Cirrhosis Drug market research report provides the detailed analysis from various regions and also contains the detailed analysis of country. Along with market revenue, market value report also offers the forecast analysis for the following countries and regions. Global Primary Biliary Cirrhosis Drug market report covers the various geographical regions such as North America, Asia-Pacific, Europe, Latin America, and Middle East & Africa. Also, various countries included are Canada, U.K., France, the U.S., Japan, China, India, and Germany and so on.

North America Region for Primary Biliary Cirrhosis Drug Market: Value and Forecast
  • U.S.
  • Canada
 
Europe Region for Primary Biliary Cirrhosis Drug Market: Value and Forecast
  • UK
  • Germany
  • France
  • Rest of the Europe
 
Asia Pacific Region for Primary Biliary Cirrhosis Drug Market: Value and Forecast
  • China
  • Japan
  • India
  • Rest of the Asia Pacific
 
Latin America Region for Primary Biliary Cirrhosis Drug Market: Value and Forecast
  • Mexico
  • Brazil
  • Rest of the Latin America
 
Middle East and Africa for Primary Biliary Cirrhosis Drug Market: Value and Forecast
  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa



Global Primary Biliary Cirrhosis Drug Market Segmentation by Type:
On the basis of product type, global Primary Biliary Cirrhosis Drug market research report provides the production, revenue, price, and market share and growth rate of each type, primarily split into: Budesonide, FFP-104, GSK-2330672, MBX-8025, NGM-282, Others

Global Primary Biliary Cirrhosis Drug Market Segmentation by Applications:
On the basis of the end users/applications, Primary Biliary Cirrhosis Drug research report analyze the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including: Clinic, Hospital, Others

Major Key Players for Global Primary Biliary Cirrhosis Drug Market:
The Primary Biliary Cirrhosis Drug market research report offers the company profile of major key players including progress trends, competitive landscape breakdown, and key in regions development status. AlbireoPharma, CymaBay Therapeutics, Inc., Dr. Falk Pharma GmbH, Enanta Pharmaceuticals, Inc., GlaxoSmithKline Plc, Intercept Pharmaceuticals, Inc., Johnson & Johnson, MediGene AG, NGM Biopharmaceuticals, Inc., Virobay Inc.

Important Points Covered by Report:
  • To analyze the value of the Primary Biliary Cirrhosis Drug market, according to the key region.
  • To study the Primary Biliary Cirrhosis Drug market current trends, prospects and also their participation in the entire sector.
  • Report consists the in-depth information related to the region/countries, major key players, current trends and their analysis, product type, applications, and other background information
  • Report provides the detailed information about drivers, restraints and future scope of Primary Biliary Cirrhosis Drug market.
  • Report covers the information about historic data analysis as well as forecast period analysis.

Global Primary Biliary Cirrhosis Drug research report consist the information about overall sales and revenue during the historic and forecasted period of 2018 to 2028. Additionally, this report covers the inside and out factual examination and the market elements and requests which give an entire situation of the business.

Key Analytical Areas:
The report aims to offer a complete solution to various businesses operating in the Primary Biliary Cirrhosis Drug market in making strategic decisions based on credible information and actionable insights. Thereby, the report covers various aspects of your requirements such as industry overview, market dynamics, regional analysis and competitive landscape. The report aims to provide insights to businesses in the Primary Biliary Cirrhosis Drug market for numerous purposes such as:

    1. Strategic Decision Making:
With the help of this report, key decision makers can quickly analyze and identify growth opportunities in terms of numerous segments across various geographical regions. Thereby, this report enables organizations to identify and make strategic investments in specific market segments in order to gain maximum return on investment.

     2. Actionable Insights:
The report offers a deep dive into how companies are leveraging market conditions to make the most in the Primary Biliary Cirrhosis Drug market. Thereby, the report offers numerous actionable insights into the best practices and key success factors relevant in the Primary Biliary Cirrhosis Drug market. Using the insights included in the report, businesses can make quick decisions to achieve success in business operations.

     3. Competitive Snapshot:
In addition, to detailed information on the companies operating in the Primary Biliary Cirrhosis Drug market, the report also includes a competitive snapshot of all the companies covered in the report. Thereby, this offers a visual representation of how all the companies stand comparatively based on their competencies, geographic presence, market hold, years of operations, employee and financial strength, among others.

Have query on this report?

Make an Enquiry
1. Preface
     1.1. Report Scope and Description
     1.2. Research Methodology
          1.2.1. Phase I-Secondary Research
          1.2.2. Phase II-Primary Research
          1.2.3. Phase II-Expert Panel Review
          1.2.4. Assumptions
          1.2.5. Approach Adopted

2. Executive Summary
     2.1. Global Primary Biliary Cirrhosis Drug Market Snapshot
          2.1.1. Global Primary Biliary Cirrhosis Drug Market By Type,2019
               2.1.1.1.Budesonide
               2.1.1.2.FFP-104
               2.1.1.3.GSK-2330672
               2.1.1.4.MBX-8025
               2.1.1.5.NGM-282
               2.1.1.6.Others
          2.1.2. Global Primary Biliary Cirrhosis Drug Market By Application,2019
               2.1.2.1.Clinic
               2.1.2.2.Hospital
               2.1.2.3.Others
          2.1.3. Global Primary Biliary Cirrhosis Drug Market By End-use,2019
          2.1.4. Global Primary Biliary Cirrhosis Drug Market By Geography,2019

3. Global Primary Biliary Cirrhosis Drug Market Dynamics
     3.1. Market Overview
     3.2. Market Inclination Insights Analysis
     3.3. Drivers
     3.4. Challenges
     3.5. Future Prospects
     3.6. Impact Analysis of Drivers and Challenges During the Forecast Period, (2020-2028)

4. Global Primary Biliary Cirrhosis Drug Market Size (US$), By Type, 2018 – 2028 
     4.1. Overview
          4.1.1. Market Share Analysis By Type, 2019 vs.2028
          4.1.2. Attractive Investment Proposition By Type, 2020
     4.2. Global Primary Biliary Cirrhosis Drug Market Size (US$), By Type, 2018 – 2028

5. Global Primary Biliary Cirrhosis Drug Market Size (US$), By Application, 2018 – 2028 
     5.1. Overview
          5.1.1. Market Share Analysis By Application, 2019 vs.2028
          5.1.2. Attractive Investment Proposition By Application, 2020
     5.2. Global Primary Biliary Cirrhosis Drug Market Size (US$), By Application, 2018 – 2028

6. Global Primary Biliary Cirrhosis Drug Market Size (US$), By End-use, 2018 – 2028 
     6.1. Overview
          6.1.1. Market Share Analysis By End-use, 2019 vs.2028
          6.1.2. Attractive Investment Proposition By End-use, 2020
     6.2. Global Primary Biliary Cirrhosis Drug Market Size (US$), By End-use, 2018 – 2028

7. Global Primary Biliary Cirrhosis Drug Market Size (US$), By Geography, 2018 – 2028
     7.1. Overview
          7.1.1. Market Share Analysis by Geography, 2019 vs. 2028
          7.1.2. Attractive Investment Proposition by Geography, 2020
     7.2. North America Primary Biliary Cirrhosis Drug Market Analysis, 2018 – 2028 
          7.2.1. North America Primary Biliary Cirrhosis Drug Market Size (US$), By Country, 2018 – 2028 
               7.2.1.1. U.S.
               7.2.1.2. Canada
          7.2.2. North America Primary Biliary Cirrhosis Drug Market Size (US$), By Type, 2018 – 2028
          7.2.3. North America Primary Biliary Cirrhosis Drug Market Size (US$), By Application, 2018 – 2028
          7.2.4. North America Primary Biliary Cirrhosis Drug Market Size (US$), By End-use, 2018 – 2028
     7.3. Europe Primary Biliary Cirrhosis Drug Market Analysis, 2018 – 2028 
          7.3.1.  Europe Primary Biliary Cirrhosis Drug Market Size (US$), By Country, 2018 – 2028 
               7.3.1.1. U.K.
               7.3.1.2. Germany
               7.3.1.3. France
               7.3.1.4. Rest of Europe
          7.3.2. Europe Primary Biliary Cirrhosis Drug Market Size (US$), By Type, 2018 – 2028
          7.3.3. Europe Primary Biliary Cirrhosis Drug Market Size (US$), By Application, 2018 – 2028
          7.3.4. Europe Primary Biliary Cirrhosis Drug Market Size (US$), By End-use, 2018 – 2028
     7.4. Asia Pacific Primary Biliary Cirrhosis Drug Market Analysis , 2018 – 2028
          7.4.1.  Asia Pacific Primary Biliary Cirrhosis Drug Market Size (US$), By Country, 2018 – 2028 
               7.4.1.1. China
               7.4.1.2. Japan
               7.4.1.3. India
               7.4.1.4. Rest of Asia Pacific
          7.4.2. Asia Pacific Primary Biliary Cirrhosis Drug Market Size (US$), By Type, 2018 – 2028
          7.4.3. Asia Pacific Primary Biliary Cirrhosis Drug Market Size (US$), By Application, 2018 – 2028
          7.4.4. Asia Pacific Primary Biliary Cirrhosis Drug Market Size (US$), By End-use, 2018 – 2028
     7.5. Latin America Primary Biliary Cirrhosis Drug Market Analysis, 2018 – 2028 
          7.5.1.  Latin America Primary Biliary Cirrhosis Drug Market Size (US$), By Country, 2018 – 2028 
               7.5.1.1. Brazil
               7.5.1.2. Mexico
               7.5.1.3. Rest of Latin America
          7.5.2. Latin America Primary Biliary Cirrhosis Drug Market Size (US$), By Type, 2018 – 2028
          7.5.3. Latin America Primary Biliary Cirrhosis Drug Market Size (US$), By Application, 2018 – 2028
          7.5.4. Latin America Primary Biliary Cirrhosis Drug Market Size (US$), By End-use, 2018 – 2028
     7.6. Middle East & Africa (MEA) Primary Biliary Cirrhosis Drug Market Analysis, 2018 – 2028 
          7.6.1.  MEA Primary Biliary Cirrhosis Drug Market Size (US$), By Region, 2018 – 2028 
               7.6.1.1. GCC Countries
               7.6.1.2. South Africa
               7.6.1.3. Rest of MEA
          7.6.2. MEA Primary Biliary Cirrhosis Drug Market Size (US$), By Type, 2018 – 2028
          7.6.3. MEA Primary Biliary Cirrhosis Drug Market Size (US$), By Application, 2018 – 2028
          7.6.4. MEA Primary Biliary Cirrhosis Drug Market Size (US$), By End-use, 2018 – 2028

8. Company Profiles
     8.1. Competitive Analysis 
     8.2. Market Positioning of Key Vendors 
     8.3. Key Strategies adopted by the Leading Players
     8.4. Key Primary Biliary Cirrhosis Drug Providers
        8.4.1 AlbireoPharma
                8.1.1 Business Description
                8.1.2 AlbireoPharma Geographic Operations
                8.1.3 AlbireoPharma Financial Information
                8.1.4 AlbireoPharma Product Positions/Portfolio
                8.1.5 AlbireoPharma Key Developments
        8.4.2 CymaBay Therapeutics, Inc.
                8.2.1 Business Description
                8.2.2 CymaBay Therapeutics, Inc. Geographic Operations
                8.2.3 CymaBay Therapeutics, Inc. Financial Information
                8.2.4 CymaBay Therapeutics, Inc. Product Positions/Portfolio
                8.2.5 CymaBay Therapeutics, Inc. Key Developments
        8.4.3 Dr. Falk Pharma GmbH
                8.3.1 Business Description
                8.3.2 Dr. Falk Pharma GmbH Geographic Operations
                8.3.3 Dr. Falk Pharma GmbH Financial Information
                8.3.4 Dr. Falk Pharma GmbH Product Positions/Portfolio
                8.3.5 Dr. Falk Pharma GmbH Key Developments
        8.4.4 Enanta Pharmaceuticals, Inc.
                8.4.1 Business Description
                8.4.2 Enanta Pharmaceuticals, Inc. Geographic Operations
                8.4.3 Enanta Pharmaceuticals, Inc. Financial Information
                8.4.4 Enanta Pharmaceuticals, Inc. Product Positions/Portfolio
                8.4.5 Enanta Pharmaceuticals, Inc. Key Developments
        8.4.5 GlaxoSmithKline Plc
                8.5.1 Business Description
                8.5.2 GlaxoSmithKline Plc Geographic Operations
                8.5.3 GlaxoSmithKline Plc Financial Information
                8.5.4 GlaxoSmithKline Plc Product Positions/Portfolio
                8.5.5 GlaxoSmithKline Plc Key Developments
        8.4.6 Intercept Pharmaceuticals, Inc.
                8.6.1 Business Description
                8.6.2 Intercept Pharmaceuticals, Inc. Geographic Operations
                8.6.3 Intercept Pharmaceuticals, Inc. Financial Information
                8.6.4 Intercept Pharmaceuticals, Inc. Product Positions/Portfolio
                8.6.5 Intercept Pharmaceuticals, Inc. Key Developments
        8.4.7 Johnson & Johnson
                8.7.1 Business Description
                8.7.2 Johnson & Johnson Geographic Operations
                8.7.3 Johnson & Johnson Financial Information
                8.7.4 Johnson & Johnson Product Positions/Portfolio
                8.7.5 Johnson & Johnson Key Developments
        8.4.8 MediGene AG
                8.8.1 Business Description
                8.8.2 MediGene AG Geographic Operations
                8.8.3 MediGene AG Financial Information
                8.8.4 MediGene AG Product Positions/Portfolio
                8.8.5 MediGene AG Key Developments
        8.4.9 NGM Biopharmaceuticals, Inc.
                8.9.1 Business Description
                8.9.2 NGM Biopharmaceuticals, Inc. Geographic Operations
                8.9.3 NGM Biopharmaceuticals, Inc. Financial Information
                8.9.4 NGM Biopharmaceuticals, Inc. Product Positions/Portfolio
                8.9.5 NGM Biopharmaceuticals, Inc. Key Developments
        8.4.10 Virobay Inc.
                8.10.1 Business Description
                8.10.2 Virobay Inc. Geographic Operations
                8.10.3 Virobay Inc. Financial Information
                8.10.4 Virobay Inc. Product Positions/Portfolio
                8.10.5 Virobay Inc. Key Developments

LIST OF TABLES

TABLE 1 Market Snapshot: Global Primary Biliary Cirrhosis Drug Market 
TABLE 2 Impact Indicators 
TABLE 3 Impact Analysis of Drivers and Restraints 
TABLE 4 North America Primary Biliary Cirrhosis Drug Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 5 North America Primary Biliary Cirrhosis Drug Market Revenue, By Application, 2018 – 2028 (US$ Mn) 
TABLE 6 North America Primary Biliary Cirrhosis Drug Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 7 Europe Primary Biliary Cirrhosis Drug Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 8 Europe Primary Biliary Cirrhosis Drug Market Revenue, By Application, 2018 – 2028 (US$ Mn) 
TABLE 9 Europe Primary Biliary Cirrhosis Drug Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 10 Asia Pacific Primary Biliary Cirrhosis Drug Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 11 Asia Pacific Primary Biliary Cirrhosis Drug Market Revenue, By Application, 2018 – 2028 (US$ Mn) 
TABLE 12 Asia Pacific Primary Biliary Cirrhosis Drug Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 13 Latin America Primary Biliary Cirrhosis Drug Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 14 Latin America Primary Biliary Cirrhosis Drug Market Revenue, By Application, 2018 – 2028 (US$ Mn) 
TABLE 15 Latin America Primary Biliary Cirrhosis Drug Market Revenue, By End-use, 2018 – 2028 (US$ Mn)
TABLE 16 MEA Primary Biliary Cirrhosis Drug Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 17 MEA Primary Biliary Cirrhosis Drug Market Revenue, By Application, 2018 – 2028 (US$ Mn) 
TABLE 18 MEA Primary Biliary Cirrhosis Drug Market Revenue, By End-use, 2018 – 2028 (US$ Mn)

LIST OF FIGURES

FIG. 1 Global Primary Biliary Cirrhosis Drug: Market Segmentation 
FIG. 2 Global Primary Biliary Cirrhosis Drug Market: Research Methodology 
FIG. 3 Top-Down and Bottom-up Approach 
FIG. 4 Global Primary Biliary Cirrhosis Drug Market, By Type, 2019 (US$ Mn) 
FIG. 5 Global Primary Biliary Cirrhosis Drug Market, By Application, 2019 (US$ Mn) 
FIG. 6 Global Primary Biliary Cirrhosis Drug Market, By End-use, 2019 (US$ Mn) 
FIG. 7 Global Primary Biliary Cirrhosis Drug Market, By Geography, 2019 (US$ Mn) 
FIG. 8 Global Primary Biliary Cirrhosis Drug Market Revenue and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG. 9 Attractive Investment Proposition 
FIG. 10 Market Positioning of Key Primary Biliary Cirrhosis Drug Providers, 2019
FIG. 11 Global Primary Biliary Cirrhosis Drug Market Revenue Contribution, By Type, 2019 & 2028 (Value %) 
FIG. 12 Global Primary Biliary Cirrhosis Drug Market Revenue Contribution, By Application, 2019 & 2028 (Value %) 
FIG. 13 Global Primary Biliary Cirrhosis Drug Market Revenue Contribution, By End-use, 2019 & 2028 (Value %) 
FIG. 14 North America Primary Biliary Cirrhosis Drug Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 15 Europe Primary Biliary Cirrhosis Drug Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 16 Asia Pacific Primary Biliary Cirrhosis Drug Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 17 Latin America Primary Biliary Cirrhosis Drug Market Revenue, 2018 – 2028, (US$ Mn)
FIG. 18 MEA Primary Biliary Cirrhosis Drug Market Revenue, 2018 – 2028, (US$ Mn)

Key Takeaways:

1. Market value and estimate of the Primary Biliary Cirrhosis Drug market for the period from 2020 to 2028
2. Compounded annual growth rate (CAGR%) for individual segments in various regional markets for a period from 2020 to 2028
3. Value chain analysis
4. Market share study combined with competitive landscape of major players
5. Profiles of major market players covering overall business operations, geographic occurrence, product portfolio, financial status and news coverage 

List of Tables

TABLE  Market Snapshot: Global Primary Biliary Cirrhosis Drug Market
TABLE  Impact Pointers
TABLE  Impact Analysis of Drivers and Restraints
TABLE  North America Primary Biliary Cirrhosis Drug Market Value, By Segment1, 2018 – 2028
TABLE  North America Primary Biliary Cirrhosis Drug Market Value, By Segment2, 2018 – 2028
TABLE  North America Primary Biliary Cirrhosis Drug Market Value, By Country, 2018 – 2028
TABLE  Europe Primary Biliary Cirrhosis Drug Market Value, By Segment1, 2018 – 2028
TABLE  Europe Primary Biliary Cirrhosis Drug Market Value, By Segment2, 2018 – 2028
TABLE  Europe Primary Biliary Cirrhosis Drug Market Value, By Country, 2018 – 2028
TABLE  Asia Pacific Primary Biliary Cirrhosis Drug Market Value, By Segment1, 2018 – 2028
TABLE  Asia Pacific Primary Biliary Cirrhosis Drug Market Value, By Segment2, 2018 – 2028
TABLE  Asia Pacific Primary Biliary Cirrhosis Drug Market Value, By Country, 2018 – 2028
TABLE  Latin America Primary Biliary Cirrhosis Drug Market Value, By Segment1, 2018 – 2028
TABLE  Latin America Primary Biliary Cirrhosis Drug Market Value, By Segment2, 2018 – 2028
TABLE  Latin America Primary Biliary Cirrhosis Drug Market Value, By Country, 2018 – 2028
TABLE  MEA Primary Biliary Cirrhosis Drug Market Value, By Segment1, 2018 – 2028
TABLE  MEA Primary Biliary Cirrhosis Drug Market Value, By Segment2, 2018 – 2028
TABLE  MEA Primary Biliary Cirrhosis Drug Market Value, By Country, 2018 – 2028
TABLE  AlbireoPharma: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  CymaBay Therapeutics, Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Dr. Falk Pharma GmbH: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Enanta Pharmaceuticals, Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  GlaxoSmithKline Plc: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Intercept Pharmaceuticals, Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Johnson & Johnson: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  MediGene AG: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  NGM Biopharmaceuticals, Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Virobay Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
 

List of Figures

FIG.  Global Primary Biliary Cirrhosis Drug Market: Research Methodology
FIG.  Top-Down and Bottom Up Approach
FIG.  Global Primary Biliary Cirrhosis Drug Market, By Segment1, 2019 (US$ Mn)
FIG.  Global Primary Biliary Cirrhosis Drug Market, By Segment2, 2019 (US$ Mn)
FIG.  Global Primary Biliary Cirrhosis Drug Market, By Geography, 2019 (US$ Mn)
FIG.  Global Primary Biliary Cirrhosis Drug Market Value and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG.  Attractive Investment Proposition
FIG.  Market Positioning of Key Primary Biliary Cirrhosis Drug Providers, 2016
FIG.  Global Primary Biliary Cirrhosis Drug Market Value Share, By Segment1, 2019 & 2028 (% Value)
FIG.  Global Budesonide Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global FFP-104 Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global GSK-2330672 Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global MBX-8025 Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global NGM-282 Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Others Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Primary Biliary Cirrhosis Drug Market Value Share, By Segment2, 2019 & 2028 (% Value)
FIG.  Global Clinic Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Hospital Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Others Market Value, 2018 – 2028, (US$ Mn)
FIG.  U.S. Primary Biliary Cirrhosis Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  Canada Primary Biliary Cirrhosis Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  UK Primary Biliary Cirrhosis Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  Germany Primary Biliary Cirrhosis Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  France Primary Biliary Cirrhosis Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Europe Primary Biliary Cirrhosis Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  China Primary Biliary Cirrhosis Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  Japan Primary Biliary Cirrhosis Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  India Primary Biliary Cirrhosis Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Asia Pacific Primary Biliary Cirrhosis Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  Mexico Primary Biliary Cirrhosis Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  Brazil Primary Biliary Cirrhosis Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Latin America Primary Biliary Cirrhosis Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  GCC Countries Primary Biliary Cirrhosis Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  South Africa Primary Biliary Cirrhosis Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of MEA Primary Biliary Cirrhosis Drug Market Value, 2018 – 2028, (US$ Mn)